Company Overview and News

 
Galan Lithium’s geophysical survey expands lithium potential in Argentina

2018-10-04 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) has received promising results from a second resistivity survey conducted at its Candelas prospect within the Hombre Muerto Lithium Project in Catamarca Province, Argentina.
GLN DMI

 
Galan Lithium making its mark on 'one of the best places in Argentina's lithium triangle'

2018-08-28 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) managing director JP Vargas speaks to Proactive Investors about the explorer’s potentially large scale Salar de Hombre Muerto Lithium Project in Argentina’s Catamarca Province, also known as the ‘lithium triangle.’
GLN GXY GALXF DMI

 
Online retailer Kogan is the best performer in week two

2018-08-24 smh.com.au
Money reader Joan Ponsford had an outstanding run in week two of the six-week Shares Race as her pick of Kogan fired-up, taking her from fifth to second place.
DMI

3
Galan Lithium reveals third director share increase this month

2018-08-21 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) has revealed that managing director Juan Pablo Vargas de la Vega has increased his shareholding in the company through on-market purchases.
GLN RTPPF GXY GALXF RIO RIO RIO FMC RTNTF DMI

1
Galan Lithium to survey shallow brines at Argentine lithium project

2018-08-20 proactiveinvestors.com.au
Galan Lithium Ltd (ASX:GLN) has begun a new round of geophysical surveys aimed at extending brine units at its Salar de Hombre Muerto Lithium Project in Argentina’s Catamarca Province.
GLN GXY GALXF FMC DMI SQM

14
Dempsey Minerals sky high as it pursues lithium strategy in Argentina

2018-06-29 proactiveinvestors.com.au
Dempsey Minerals Ltd (ASX:DMI) is riding the lithium wave with its primary focus on the prolific Lithium Triangle area of Argentina and shares reflect the strategy.
GXY GALXF FTI.WI FMC DMI SQM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:DMI / DEMPSEY MINERALS LIMITED on message board site Silicon Investor.

Questions and Answers with SI Admin (s) Questions and Answers with SI Admin (s) Questions and Answers with SI Admin (s) Dmitryu0027s Random Feed Dmitryu0027s Random Feed Dmitryu0027s Random Feed
Describe the Current Administration in One Word Describe the Current Administration in One Word Describe the Current Administration in One Word Seabridge seabf sea.v -- Goldmine in the Making Seabridge seabf sea.v -- Goldmine in the Making Seabridge seabf sea.v -- Goldmine in the Making
African Goldmine African Goldmine African Goldmine True Confessions -- Admit it -- you bought u003ciu003ethatu003c/iu003e stock True Confessions -- Admit it -- you bought u003ciu003ethatu003c/iu003e stock True Confessions -- Admit it -- you bought u003ciu003ethatu003c/iu003e stock
Goldminco Consolidated Mining Corp. GMC (was GMO) Goldminco Consolidated Mining Corp. GMC (was GMO) Goldminco Consolidated Mining Corp. GMC (was GMO) Bush Administrationu0027s Media Manipulation--MediaGate? Bush Administrationu0027s Media Manipulation--MediaGate? Bush Administrationu0027s Media Manipulation--MediaGate?
IDM Pharma Inc. (IDMI) IDM Pharma Inc. (IDMI) IDM Pharma Inc. (IDMI) Recycler Technology becomes Goldmine Recycler Technology becomes Goldmine Recycler Technology becomes Goldmine